Myocardial Protection With Adenosine Preconditioning

Heart Defects, Congenital Clinical Trial

Official title: Study of Myocardial Protection in Pediatric Cardiac Surgery With Adenosine Preconditioning

Status Completed

Clinical Trial Summary

Adenosine has been proved to be an important mediator of myocardial protection induced by ischemic preconditioning. The hypothesis of this study is that adenosine preconditioning can provide additional myocardial protection in the setting of pediatric open heart surgery with cardioplegia and cardiopulmonary bypass.

Clinical Trial Description

Adenosine has been used for diagnosis and treatment of cardiovascular diseases for many years. New progresses in myocardial protection in the settings of acute myocardial infarction treatment put forward the its clinical use to a broader field. But the safety and effectiveness of its use in myocardial protection in the setting of open heart surgery has not been investigated intensively. Our primary results suggested that adenosine preconditioning could decrease the release of myocardial serum markers, such as cTnI. This study will focus on the safety and effectiveness of adenosine in the field of pediatric myocardial protection during surgery repair of congenital heart defects with CPB and cardioplegia. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adenosine
• Cardiac Surgical Procedures
• Congenital Abnormalities
• Heart Defects, Congenital
• Myocardial Reperfusion Injury
• Reperfusion Injury

• NCT number: NCT00881686
• Study type: Interventional
• Source: Xijing Hospital
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: June 2008
• Completion date: December 2008